Original Article
Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast Cancer
N Engl J Med 2006; 355:1851-1862November 2, 2006
- Abstract
Background
The National Epirubicin Adjuvant Trial (NEAT) and the BR9601 trial examined the efficacy of anthracyclines in the adjuvant treatment of early breast cancer.
Methods
In NEAT, we compared four cycles of epirubicin followed by four cycles of cyclophosphamide, methotrexate, and fluorouracil (CMF) with six cycles of CMF alone. In the BR9601 trial, we compared four cycles of epirubicin followed by four cycles of CMF, with eight cycles of CMF alone every 3 weeks. The primary end points were relapse-free and overall survival. The secondary end points were adverse effects, dose intensity, and quality of life.
Results
The two trials included 2391 women with early breast cancer; the median follow-up was 48 months. Relapse-free and overall survival rates were significantly higher in the epirubicin–CMF groups than in the CMF-alone groups (2-year relapse-free survival, 91% vs. 85%; 5-year relapse-free survival, 76% vs. 69%; 2-year overall survival, 95% vs. 92%; 5-year overall survival, 82% vs. 75%; P<0.001 by the log-rank test for all comparisons). Hazard ratios for relapse (or death without relapse) (0.69; 95% confidence interval [CI], 0.58 to 0.82; P<0.001) and death from any cause (0.67; 95% CI, 0.55 to 0.82; P<0.001) favored epirubicin plus CMF over CMF alone. Independent prognostic factors were nodal status, tumor grade, tumor size, and estrogen-receptor status (P<0.001 for all four factors) and the presence or absence of vascular or lymphatic invasion (P=0.01). These factors did not significantly interact with the effect of epirubicin plus CMF. The overall incidence of adverse effects was significantly higher with epirubicin plus CMF than with CMF alone but did not significantly affect the delivered-dose intensity or the quality of life.
Conclusions
Epirubicin plus CMF is superior to CMF alone as adjuvant treatment for early breast cancer. (ClinicalTrials.gov number, NCT00003577.)
Media in This Article
Figure 1
Enrollment, Randomization, Receipt of Study Treatment, and Follow-up in the Two Trials.Figure 2
Kaplan–Meier Estimates of Overall Survival (Panel A) and Relapse-free Survival (Panel B) According to Treatment.Article Activity
- Article
The National Epirubicin Adjuvant Trial (NEAT) and the BR9601 trial were designed jointly by English and Scottish investigators in 1994 and 1995 to determine the value of anthracyclines in the adjuvant treatment of early breast cancer. At that time, a combination of cyclophosphamide, methotrexate, and fluorouracil was standard treatment for early breast cancer in the United Kingdom. The role of anthracyclines had not been addressed in the 1990 Oxford Overview of the treatment of early breast cancer,1 and despite the activity of anthracyclines in metastatic disease,2 data from adjuvant trials were inconsistent. Concerns about adverse effects and effects on the quality of life also delayed the inclusion of anthracyclines in adjuvant chemotherapy combinations.
In 1991, the importance of scheduling the administration of anthracyclines became evident. Studies in Milan3 showed that a block-sequential schedule of four cycles of doxorubicin at a dose of 75 mg per square meter of body-surface area every 3 weeks, followed by eight cycles of CMF every 3 weeks, was superior to a 2:1 alternating regimen of the same drugs, at the same cumulative doses during the same period.4,5 A companion study failed to show the superiority of 8 cycles of CMF followed by 4 cycles of doxorubicin over 12 cycles of CMF.6 These observations were consistent with mathematical models that predicted better outcomes with block-sequential therapy7,8 than with an alternating regimen of non–cross-resistant agents.9,10
For these reasons, we adopted a block-sequential schedule for the anthracycline-containing regimens used in NEAT and the BR9601 trial, with three modifications. First, we used epirubicin instead of doxorubicin to reduce treatment-related adverse effects.11 Second, in NEAT, we administered classic CMF (see the glossary for chemotherapy schedules)12 because of its superior efficacy in metastatic breast cancer13 and the importance of dose delivery of CMF in early breast cancer.14 In the BR9601 trial, the classic CMF regimen was modified, with all three drugs given intravenously once every 3 weeks, to minimize the need for patients to travel to a specialized center in Scotland, since this is an area of low population density and a large proportion of enrollees did not live close to such a center. Third, we shortened the duration of therapy by cutting the sequentially administered CMF to four cycles in the anthracycline groups of both trials. The control treatments in each trial were of equal duration, with six cycles of classic CMF in NEAT and eight cycles of the CMF schedule in the BR9601 trial.
Methods
Study Design
We designed both phase 3 trials to test the hypothesis that, as compared with CMF alone, four cycles of epirubicin plus four cycles of CMF would improve overall and relapse-free survival among women with early breast cancer. A parallel study design was used to maximize recruitment north and south of the border between England and Scotland, with NEAT predominantly recruiting women from the United Kingdom and the BR9601 trial predominantly recruiting women from Scotland (see the Supplementary Appendix, available with the full text of this article at www.nejm.org). The trials were coordinated in parallel, with a joint analysis of outcomes from a single amalgamated data set, planned at the outset and facilitated by similar approaches to stratification and data collection (Figure 1Figure 1
Enrollment, Randomization, Receipt of Study Treatment, and Follow-up in the Two Trials.). Both trials were approved by a multicenter research ethics committee and by the local research ethics committee at each participating hospital. Pharmacia did not participate in the study design, data collection or analysis, or preparation of the manuscript.Patients
Women with completely excised early breast cancer who required adjuvant chemotherapy and could start treatment within 10 weeks after surgery were eligible for the study. Additional eligibility criteria were adequate renal, hepatic, and bone marrow function; the absence of previous exposure to chemotherapy or radiotherapy; the absence of previous or concomitant cancer; and provision of written informed consent.
Treatment
In each trial, patients were assigned to epirubicin plus CMF or CMF alone with the use of a permuted-block, 1:1 randomization scheme (Figure 1). Treatment assignments were made by telephone to central locations. Both NEAT and the BR9601 trial stratified patients according to center, age, and nodal status; NEAT also stratified patients according to planned radiotherapy schedule. NEAT used epirubicin plus CMF for the anthracycline group and classic CMF alone for the control group (see the Glossary). BR9601 used epirubicin plus the modified CMF regimen for the anthracycline group and the modified CMF regimen alone for the control group (see the Glossary). Neither trial restricted adjuvant hormonal treatment. Of the 1458 patients in NEAT for whom data were available regarding clinicians' proposals for adjuvant tamoxifen, 68% were to receive adjuvant tamoxifen, and 32% were not. Scheduling information was available for 843 of these patients (452 in the epirubicin–CMF group and 391 in the CMF group); 46% were to receive tamoxifen concurrently with chemotherapy (48% of those in the epirubicin–CMF group and 45% of those in the CMF group), and 54% were to receive tamoxifen after chemotherapy (52% of those in the epirubicin–CMF group and 55% of those in the CMF group).
Statistical Analysis
A combined enrollment of 2000 patients was required for the study to have a statistical power of 85% to detect an absolute difference of 7% in both overall and relapse-free survival between the treatment groups, with a 5% (two-sided) level of significance. However, in NEAT, the goal was to enroll 2000 patients independently in order to allow an unbiased analysis of the specified treatment regimens. In the BR9601 trial, the goal was to enroll an additional 300 to 500 patients in order to increase the statistical power of the comparison between epirubicin plus CMF and CMF alone in a planned joint analysis.
Relapse-free and Overall Survival
The primary outcome measures were relapse-free and overall survival. Relapse-free survival was calculated from the date of surgery to the date of a first relapse, to the date of death without relapse, or to the date of data censoring (for women who remained alive and relapse-free). Overall survival was calculated from the date of surgery to the date of death or to the date of data censoring (for women who remained alive). Survival curves were constructed with the use of Kaplan–Meier methods.15 We used log-rank tests to compare patient and tumor characteristics and treatments. Cox proportional-hazards models16 were constructed to evaluate and make adjustments for prognostic factors. We calculated hazard ratios for relapse (and death without relapse) and death from any cause in prognostic subgroups, and constructed forest plots.17 Secondary outcome measures were adverse effects, dose intensity, and for a subgroup of NEAT patients, the quality of life.
Adverse Effects
Common Toxicity Criteria (CTC) grades were recorded for each cycle of chemotherapy. We used chi-square tests with Bonferroni corrections for multiple comparisons to compare the treatment groups with respect to the number of patients with severe adverse effects (defined as a CTC grade ≥3, or grade 2 for alopecia).
Dose Intensity
The Supplementary Appendix describes the calculation of the course-delivered dose intensity. The treatment groups were compared with respect to the dose intensity of delivered doses in each cycle and of the full course of chemotherapy with the use of Wilcoxon rank-sum tests and chi-square tests with continuity corrections.
Quality of Life
The European Organisation for Research and Treatment of Cancer questionnaire for assessing the health-related quality of life of patients with cancer (QLQ-C30),18 their supplementary breast cancer module (QLQ-BR23),19 and the Women's Health Questionnaire20 were administered at randomization, midway through chemotherapy, at the end of chemotherapy, and 1 and 2 years after randomization. A standardized area-under-the-curve analysis21 was carried out for the quality of life during the treatment period, and changes from baseline to 1 year and from baseline to 2 years were calculated to assess long-term effects. Treatments were compared with the use of O'Brien's global rank procedure22 and Wilcoxon rank-sum tests. Scores were on a scale of 0 to 100, with higher scores representing better quality of life (either higher functional scores, lower symptom levels, or higher quality-of-life scores). Negative changes over time thus represented a decline in quality of life, and positive changes represented an improvement in quality of life.
The joint analysis of the two trials was undertaken by the Cancer Research U.K. Clinical Trials Unit, Birmingham, with the use of SAS software. Results from the first preplanned, event-driven, analysis of the primary end points for both trials are presented. Given 400 end-point events, the study would have a statistical power of 99% to detect an absolute difference of 10% between treatment groups with a 5% (two-sided) level of significance. The results for trial-specific adverse events, course-delivered dose intensity, and the quality of life are summarized here. All reported P values are two-sided. Data for all patients whose treatment involved protocol violations were analyzed within the groups to which the patients had been randomly assigned, an approach that allowed us to perform the analysis on an intention-to-treat basis.
Results
Patients
NEAT recruited 2027 patients from 111 clinicians at 65 centers between April 1996 and July 2001. The BR9601 trial began in October 1996 and closed in April 2001 after recruiting 374 patients from 26 clinicians at 10 centers. Ten patients were ineligible for the trial: 6 in NEAT (2 patients who received epirubicin plus CMF and 4 who received CMF alone) and 4 patients in BR9601 (3 patients who received epirubicin plus CMF and 1 patient who received CMF alone), principally because of metastatic breast cancer or a history of other cancer, leaving 2391 eligible patients for analysis (Figure 1).
Patients' characteristics, the type of operation, the timing of surgery (Table 1Table 1
Baseline Characteristics of the Patients.), and tumor characteristics (Table 3 of the Supplementary Appendix) were similar among the treatment groups. The clinically significant differences between the two trials included more women under the age of 50 years and more node-negative tumors in NEAT and larger tumors and more frequent mastectomies in the BR9601 trial.Treatment Compliance
Violations of the assigned protocol were noted by the trial management groups in the treatment of 15 patients: 12 in NEAT (7 assigned to receive epirubicin plus CMF, and 5 assigned to receive CMF alone) and 3 in the BR9601 trial (all assigned to receive CMF alone). All analyses included these patients in their assigned groups, according to the intention-to-treat principle.
Overall and Relapse-free Survival
After a median follow-up of 48 months, 413 women had died (17% of all 2391 eligible women, 16% of those in NEAT, and 23% of those in the BR9601 trial) (Table 4 of the Supplementary Appendix). The median time to death was 2.5 years (range, 45 days to 7 years). The main cause of death was breast cancer (in 92% of the women who died). Locoregional or distant relapse was reported in 491 women, with distant metastases predominantly in the bone, liver, or both. There were 545 events in the analysis of relapse-free survival. Follow-up was equivalent between trials and treatments (median, 48 months; range, 6 months to 7.5 years) and is continuing.
Figure 2Figure 2
Kaplan–Meier Estimates of Overall Survival (Panel A) and Relapse-free Survival (Panel B) According to Treatment. compares survival curves for the groups that received epirubicin plus CMF and the groups that received CMF alone. The rate of overall survival at 2 years was 95% in the epirubicin plus CMF group and 92% in the CMF group. The survival rate at 5 years was 82% in the epirubicin plus CMF group and 75% in the CMF group (P<0.001 by the log-rank test) (Figure 2A). The hazard ratio for death from any cause in the epirubicin plus CMF group, as compared with the CMF group, was 0.67 (95% confidence interval [CI], 0.55 to 0.82; P<0.001). The rate of relapse-free survival at 2 years was 91% in the epirubicin plus CMF group and 85% in the CMF group. At 5 years, the rate of relapse-free survival was 76% in the epirubicin plus CMF group and 69% in the CMF group (P<0.001 by the log-rank test) (Figure 2B). The hazard ratio for relapse (or death without relapse) in the epirubicin plus CMF group, as compared with the CMF group, was 0.69 (95% CI, 0.58 to 0.82; P<0.001). The results for overall survival and relapse-free survival in NEAT were similar to those in the BR9601 trial (P=0.39 for overall survival and P=0.34 for relapse-free survival) (Figure 5 of the Supplementary Appendix).Univariate analysis showed that the following factors were significantly associated with relapse-free survival: treatment (epirubicin plus CMF or CMF alone), nodal status (no positive nodes, 1 to 3 positive nodes, or ≥4 positive nodes), estrogen-receptor status (positive, negative, or unknown), tumor size (≤2 cm or >2 cm) and grade (1, 2, or 3), vascular or lymphatic invasion (reported or unreported), and type of surgery (mastectomy or breast-conserving surgery) (P<0.001 for all comparisons) (Table 2Table 2
Relapse-free Survival According to Treatment, Tumor, and Patient Characteristics.). All these factors except the type of surgery were independently associated with relapse-free survival in a multivariate analysis (Table 6 of the Supplementary Appendix). A base model of these factors confirmed that treatment was an independent prognostic factor for relapse-free survival (P<0.001). The ranking of these factors was as follows: nodal status, tumor grade, tumor size, treatment, estrogen-receptor status, and presence or absence of vascular or lymphatic invasion. The results were similar for overall survival, with the exception that vascular or lymphatic invasion was not a prognostic factor.Interaction of Treatment Effect with Prognostic Factors
Forest plots showed similar effects of treatment on relapse-free survival, regardless of nodal status, estrogen-receptor status, tumor diameter, tumor grade, age, menopausal status, performance status, surgery, and presence or absence of vascular or lymphatic invasion (Figure 5 of the Supplementary Appendix). The results of all statistical tests of heterogeneity were nonsignificant. Similar results were obtained for overall survival.
Adverse Effects of Chemotherapy
Complete information regarding adverse effects was available for 1952 of 2021 patients (97%) in NEAT and 366 of 370 patients (99%) in the BR9601 trial. In NEAT, significantly more patients in the epirubicin plus CMF group than in the CMF group reported severe alopecia (84% vs. 27%), nausea (15% vs. 7%), vomiting (12% vs. 4%), constipation (6% vs. 2%), and stomatitis (6% vs. 3%) (Table 3Table 3
Severe Adverse Effects.). In NEAT, the treatment groups did not differ significantly with respect to the proportions of patients reporting severe diarrhea (6% in both groups), infection (7% in the epirubicin plus CMF group and 5% in the CMF group), fatigue (21% and 18%, respectively), neutropenia (15% in both groups), or thrombocytopenia (1% in both groups). Neutropenic sepsis (neutropenia and infection in the same cycle) was recorded in 346 cycles (3% in each group) and by 247 patients (13%): 14% of those in the epirubicin plus CMF group and 11% of those in the CMF group.In the BR9601 trial, the proportion of patients who reported severe alopecia was significantly higher in the epirubicin plus CMF group than in the CMF group (96% vs. 76%). However, the two groups did not differ significantly with respect to the proportions of patients who reported severe nausea (16% in the epirubicin plus CMF group and 11% in the CMF group), vomiting (12% and 9%, respectively), stomatitis (4% and 3%), diarrhea (3% in both groups), infection (5% and 2%), or fatigue (25% and 17%).
Of premenopausal patients for whom data were available, 73% reported chemotherapy-related amenorrhea. The rates were similar in the two trials and in the treatment groups (in NEAT, 71% for epirubicin plus CMF and 74% for CMF alone; in the BR9601 trial, 73% for epirubicin plus CMF and 74% for CMF alone).
Deaths Attributed to Chemotherapy
Among the 2391 patients, 20 deaths were attributed to treatment-related adverse effects (1%), with a similar incidence in the two trials. Of these 20 deaths, 18 occurred in patients in NEAT (5 patients who received epirubicin plus CMF and 13 who received CMF alone). Eight of the 18 deaths were due to neutropenic sepsis (in 4 patients who received epirubicin plus CMF and 4 who received CMF alone), 5 to pulmonary emboli (in 1 patient who received epirubicin plus CMF and 4 patients who received CMF alone), and 4 to cerebrovascular accidents (all in patients who received CMF alone); autopsy failed to elucidate a cause of death in 1 patient who received CMF alone and who had a normal blood count at the time of death. Two patients died of treatment-related adverse effects in the BR9601 trial: one patient who received epirubicin plus CMF died of cholecystitis, and one patient who received CMF alone died of bronchopneumonia. In all four treatment groups in the two trials, all deaths from treatment-related adverse effects occurred during treatment with CMF. Among patients who received CMF, deaths due to treatment-related adverse effects occurred in all treatment cycles.
Delivered Dose Intensity
The excess incidence of treatment-related adverse effects among patients who received epirubicin plus CMF did not compromise the course-delivered dose intensity in either trial, in terms of either the median overall delivered-dose intensity or the proportion of patients receiving an adequate dose intensity (≥85% of planned doses). (See the Supplementary Appendix for additional information.)
Quality of Life
The 511 patients in NEAT who were included in the quality-of-life analysis were representative of the overall study population in NEAT in terms of baseline characteristics, overall survival, and relapse-free survival. During treatment, patients who received epirubicin plus classic CMF reported significantly more severe symptoms than did those who received classic CMF alone, as measured by the QLQ-BR23 questionnaire (P=0.05). An analysis of the relevant QLQ-BR23 symptom subscales identified significantly worse scores for patients who received epirubicin plus CMF than for patients who received CMF alone. These scores included “systemic therapy side effects” (median, 69 [interquartile range, 57 to 77] and 72 [interquartile range, 63 to 82], respectively; P<0.01) and “upset by hair loss” (median, 33 [interquartile range, 0 to 67] and 67 [interquartile range, 33 to 87], respectively; P<0.01). There were no other significant differences in the quality of life between the two groups during treatment. However, an analysis of changes from baseline to 1 year showed that patients who received CMF alone had less improvement in global health and a greater increase in symptoms, as measured by the QLQ-C30 questionnaire (P=0.01). The median change in global quality of life was 8.3 (interquartile range, 0 to 16.7) for patients who received epirubicin plus CMF and 0 (interquartile range, −8.3 to 16.7) for patients who received CMF alone. In addition, an analysis of the relevant symptom subscales showed that patients who received CMF alone had more dyspnea at 1 year than at baseline (median change, 0 [interquartile range, −33 to 0]) than patients who received epirubicin plus CMF (median change, 0 [interquartile range, 0 to 0]; P=0.04). An analysis of changes from baseline to 2 years showed no significant differences in the quality of life between the two groups.
Discussion
Our combined analysis of NEAT and the BR9601 trial, at a median follow-up of 48 months, shows the superiority of epirubicin plus CMF over CMF alone for the treatment of early breast cancer. The hazard ratios for relapse (or death without relapse) (0.69) and for death from any cause (0.67) were significant (P<0.001 for both comparisons), and these findings were unlikely to be due to an artifact of the slight difference between the duration of treatment in the research and control groups of the NEAT trial. Furthermore, the results were similar in the two trials, despite the differences in treatments. We can therefore attribute the advantage of epirubicin plus CMF to the epirubicin component of the combination chemotherapy.
The results of this analysis are applicable to most patients with breast cancer. There were no significant influences of estrogen-receptor status (P=0.17 by a test for heterogeneity) or tumor grade (P=0.34 by a test for trend), and even though the proportion of women younger than 50 years of age was larger in the population we studied than that in the general population of women with breast cancer, we can discern no loss of efficacy among older women (P=0.50) (Figure 5 of the Supplementary Appendix).
Severe effects were reported in less than 5% of cycles. As anticipated, there were moderate differences in the incidence of treatment-related adverse effects, with higher rates with epirubicin plus CMF than with CMF alone and a short-term reduction in the quality of life during chemotherapy. However, the majority of treatment-related deaths occurred in the CMF group (14, vs. 6 in the epirubicin plus CMF group), and all 6 deaths in the epirubicin plus CMF group occurred during the CMF phase of therapy.
In the Early Breast Cancer/Mammary5 (EBC-1/MA.5) study by the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), which compared a combination of cyclophosphamide, epirubicin, and fluorouracil (CEF) with CMF alone in premenopausal women with node-positive breast cancer,23 the rate of relapse-free survival at 5 years was 53% in the CMF group and 63% in the CEF group (P=0.009); the rate of overall survival at 5 years was 70% and 77%, respectively (P=0.03). Patients did not receive adjuvant tamoxifen in EBC-1/MA.5. The delivered dose intensity of CEF was 80 to 83%, as compared with 96% for CMF, suggesting that six cycles of CEF, with a total dose of epirubicin of 120 mg per square meter per 4-week cycle, may be a less tolerable regimen than epirubicin plus CMF (Table 7 of the Supplementary Appendix).
On the basis of the data from NEAT and the BR9601, and NCIC CTG trial, as well as data from the French Adjuvant Study Group's Early Breast Cancer 05 trial,24 which showed an advantage of FEC100 over FEC50, it is plausible that adequate doses of epirubicin, in the range of 100 to 120 mg per square meter per cycle, provide more benefit than was found in a meta-analysis of the substitution of an anthracycline for methotrexate conducted by the Early Breast Cancer Trialists Collaborative Group.25 The International Collaborative Cancer Group study,26 which compared FEC50 with classic CMF, did not show that the substitution of epirubicin (at a dose of 50 mg per square meter) for methotrexate produced significantly better results.
Analysis of the data from the NCIC CTG studies27 has shown a cumulative incidence of secondary leukemia of 2% at 8 years' follow-up among women treated with epirubicin-based adjuvant chemotherapy. The follow-up in NEAT and the BR9601 trial (48 months) is too short to assess the incidence of secondary acute myeloid leukemia, which typically occurs 2 to 4 years after anthracycline treatment.28 We found only one case — an acute promyelocytic leukemia. Although this is not the typical subtype of acute myeloid leukemia attributed to anthracyclines, an association between promyelocytic leukemia and exposure to a topoisomerase II inhibitor has been described.29,30 We do not anticipate many late cases of acute myeloid leukemia because the low cumulative dose of epirubicin in our trials reduces the risk of anthracycline-related acute myeloid leukemia.28
Block-sequential designs of single-agent anthracycline therapy followed by CMF have been used in the control groups of a number of important phase 3 clinical trials. These trials include the Anglo-Celtic trial,31 which showed no benefit of high-dose chemotherapy, and the European Cooperative Trial in Operable Breast Cancer (ECTO),32 which showed that doxorubicin and paclitaxel plus CMF was superior with respect to relapse-free survival to doxorubicin plus CMF. On the basis of the NEAT and BR9601 efficacy data, of all the taxane-containing anthracycline-based regimens that have been evaluated, doxorubicin and paclitaxel plus CMF may come closest to fully exploiting the potential of these drugs. Epirubicin plus CMF (in the same doses used in NEAT) has been used in an optional control group in a study in the United Kingdom, the Taxotere as Adjuvant Chemotherapy Trial (TACT)33 (as compared with FEC and docetaxel), and in the ongoing TACT2 (as compared with epirubicin plus capecitabine) in a bifactorial design also evaluating dose-dense epirubicin. Analysis of the role that amplification of the human epidermal growth factor receptor type 2 gene (HER2) and the topoisomerase IIα gene (TOP2A) plays in determining anthracycline sensitivity in the NEAT and BR9601 treatment populations is ongoing. At this point, there are no reported data on the safety or efficacy of trastuzumab when used concurrently with epirubicin plus CMF, although trastuzumab has been given as maintenance therapy after adjuvant treatment with epirubicin plus CMF in women with HER2-positive early breast cancer.34 Buzdar et al. reported that there were no cases of congestive cardiac failure in their trial, in which 44 patients were randomly assigned to neoadjuvant treatment with paclitaxel, followed by four cycles of the FEC regimen with or without herceptin administered concurrently for 24 weeks. However, they acknowledge that their study was too small for conclusions to be drawn about the safety of this approach.35
In conclusion, adjuvant treatment of early breast cancer with epirubicin plus CMF has significant superiority over CMF alone in terms of relapse-free survival and overall survival. Although there was a higher incidence of treatment-related adverse effects with epirubicin plus CMF, its use was associated with adverse effects on the quality of life that are similar to those associated with CMF treatment. On the basis of the results in 75 centers, we recommend epirubicin plus CMF as an option for anthracycline-based adjuvant chemotherapy in women with early breast cancer.
Supported by grants from the Cancer Research Campaign (now Cancer Research UK) and Pharmacia (now Pfizer); Pharmacia also provided epirubicin at a discount.
Dr. Poole reports having received consulting fees and lecture fees from Eli Lilly, Pfizer, Amgen UK, Sanofi-Aventis, Roche, AstraZeneca, GlaxoSmithKline, Fulcrum Pharma, and Bristol-Myers Squibb; consulting fees from Novartis; and grant support from Pfizer and Cancer Research UK. Dr. Earl reports having received consulting fees from Pfizer, Bristol-Myers Squibb, and Amgen UK; and grant support from Cancer Research UK and Eli Lilly. Dr. Dunn reports having received grant support from Cancer Research UK, Pfizer, and Merck. Drs. Agrawal, Brunt, Rea, Earl, and Mansi report having received consulting fees from AstraZeneca. Dr. Fernando reports having received grant support from Cancer Research UK. Drs. Brunt, Rea, and McAdam report having received consulting fees from Roche. Dr. O'Reilly reports having served on advisory boards for Sanofi-Aventis and Novartis and having received lecture fees from AstraZeneca, Sanofi-Aventis, and Novartis. Dr. Rea reports having received consulting fees from Pfizer, Novartis, and GlaxoSmithKline; and grant support from Pfizer and Novartis. Mr. Stanley reports having received consulting fees from Westaway Gillis, Roche, and Amgen; and lecture fees from Aventis. Dr. Leonard reports having received consulting fees and lecture fees from Pfizer, Amgen, and Roche; consulting fees from Sanofi-Aventis; lecture fees from Bioenvision; and grant support from Amgen, European Union, and Cancer Research UK. Dr. Twelves reports having received consulting fees from Chugai and Aventis; and consulting and lecture fees from Roche. No other potential conflict of interest relevant to this article was reported.
We thank the 137 clinicians, many research nurses, and 2391 patients who made these studies possible at 75 collaborative centers; the data monitoring committee (Mahesh K.B. Parmar, director, MRC Cancer Trials Office, London; Maurice L. Slevin, consultant medical oncologist, St. Bartholomew's Hospital, London; and Colin S. McArdle, consultant surgeon, Glasgow Royal Infirmary, Glasgow) for their expert review of both NEAT and the BR9601 trial; the trial coordinators for the two trials, including Lorna Stewart, Ruth Main, Paul Stroner, Jeannie Bishop, Rachel McGregor, Caroline Jevons, Michelle McDermaid, and Sarah Bowden; and Tracey Rapson, the assisting statistician for BR9601.
Source Information
From the Cancer Research U.K. Clinical Trials Unit, Institute for Cancer Studies, Birmingham (C.J.P., L.H., J.A.D., S.B., D.W.R.); Addenbrookes Hospital, Cambridge (H.M.E., K.M.); Radiotherapy and Oncology Centre, Walsgrave Hospital, Coventry (R.J.G.); Cancer Centre, Queen Elizabeth Hospital, Birmingham (D.A.S., I.N.F.); Royal Shrewsbury Hospital, Shropshire (R.K.A.); Staffordshire Oncology Centre, Staffordshire (A.M.B.); Clatterbridge Hospital, Merseyside (S.M.O.); Airedale General Hospital, Yorkshire (S.M.C.); Royal South Hampshire Hospital, Southampton (P.S.); St. George's Hospital, London (J.L.M.); City Hospital, Birmingham (A.S.); St. James's University Hospital, Leeds (P.H.); Peterborough District Hospital, Cambridgeshire (K.M.); Scottish Cancer Therapy Network, Edinburgh (L.F.); Swansea Cancer Centre, Wales (R.C.F.L.); and Bradford Royal Infirmary, Bradford (C.J.T.) — all in the United Kingdom.
Address reprint requests to Dr. Poole at the Cancer Research U.K. Clinical Trials Unit, Institute for Cancer Studies, University of Birmingham, Birmingham B15 2TT, United Kingdom, or at poolecj@aol.com.
Members of the trial management group for the National Epirubicin Adjuvant Trial (NEAT) and the Scottish Cancer Trials Breast Group (SCTBG) are listed in the Appendix.
Appendix
The following people participated in the trial management group: S. Bathers, J. Bishop, M. Brunt, L. Dodson, J. Dunn, H. Earl, I. Fernando, R. Grieve, P. Harvey, L. Hiller, H. Jarrett, C. Jevons, R. Leonard, J. Mansi, S. O'Reilly, T. Perren, C. Poole, C. Price, D. Rea, D. Spooner, A. Stanley, J. Stewart, N. Stuart, C. Twelves, J. Woods. The clinicians who recruited patients for the trial are listed in the Supplementary Appendix.
- References
References
1
Early Breast Cancer Trialists' Collaborative Group
Web of Science | Medline2
Habeshaw T ,Paul J ,Jones R , et al. Epirubicin at 2 dose levels with prednisolone as treatment for advanced breast-cancer: the results of a randomized trial. J Clin Oncol 1991;9:295-304
Web of Science | Medline3
Buzzoni R ,Bonadonna G ,Valagussa P ,Zambetti M . Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than 3 positive axillary nodes. J Clin Oncol 1991;9:2134-2140
Web of Science | Medline4
Bonadonna G ,Zambetti M ,Moliterni A ,Gianni L ,Valagussa P . Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and fluorouracil in operable breast cancer. J Clin Oncol 2004;22:1614-1620
CrossRef | Web of Science | Medline5
Bonadonna G ,Zambetti M ,Valagussa P . Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes: ten-year results. JAMA 1995;273:542-547
CrossRef | Web of Science | Medline6
Moliterni A ,Bonadonna G ,Valagussa P ,Ferrari L ,Zambetti M . Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast-cancer with one to three positive axillary nodes. J Clin Oncol 1991;9:1124-1130
Web of Science | Medline7
Norton L, Day R. Potential innovations in scheduling in cancer chemotherapy. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Important advances in oncology. Philadelphia: J.B. Lippincott, 1991:57-72.
8
Day RS . Treatment sequencing, asymmetry, and uncertainty: protocol strategies for combination chemotherapy. Cancer Res 1986;46:3876-3885
Web of Science | Medline9
Goldie JH ,Coldman AJ . A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979;63:1727-1733
Medline10
Goldie JH ,Coldman AJ ,Gudauskas GA . Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 1982;66:439-449
Medline11
Earl H ,Iddawela M . Epirubicin as adjuvant therapy in breast cancer. Expert Rev Anticancer Ther 2004;4:189-195
CrossRef | Medline12
Goldhirsch A ,Colleoni M ,Coates AS ,Castiglione-Gertsch M ,Gelber RD . Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: are all CMFs alike? Ann Oncol 1998;9:489-493
CrossRef | Web of Science | Medline13
Engelsman E ,Klijn JC ,Rubens RD , et al. “Classical CMF” versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer: an EORTC Breast Cancer Co-operative Group Phase III Trial (10808). Eur J Cancer 1991;27:966-970
CrossRef | Web of Science | Medline14
Bonadonna G ,Valagussa P . Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981;304:10-15
Full Text | Web of Science | Medline15
Kaplan EL ,Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
CrossRef | Web of Science16
Cox DR . Regression models and life-tables. J R Stat Soc [B] 1972;34:187-22017
Early Breast Cancer Trialists' Collaborative Group. Treatment of early breast cancer. Vol. 1. Worldwide evidence 1985-1990. Oxford, England: Oxford University Press, 1990.
18
Aaronson NK ,Ahmedzai S ,Bergman B , et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376
CrossRef | Web of Science | Medline19
Sprangers MAG ,Groenvold M ,Arraras JI , et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol 1996;14:2756-2768
Web of Science | Medline20
Hunter MS . The Women's Health Questionnaire: a measure of mid-aged women's perceptions of their emotional and physical health. Psychol Health 1992;7:45-54
CrossRef | Web of Science21
Qian W ,Parmar MKB ,Sambrook RJ ,Fayers PM ,Girling DJ ,Stephens RJ . Analysis of messy longitudinal data from a randomised clinical trial. Stat Med 2000;19:2657-2674
CrossRef | Web of Science | Medline22
O'Brien PC . Procedures for comparing samples with multiple endpoints. Biometrics 1984;40:1079-1087
CrossRef | Web of Science | Medline23
Levine MN ,Bramwell VH ,Pritchard KI , et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. J Clin Oncol 1998;16:2651-2658
Web of Science | Medline24
French Adjuvant Study Group
Web of Science | Medline25
Early Breast Cancer Trialists' Collaborative Group
CrossRef | Web of Science | Medline26
Coombes RC ,Bliss JM ,Wils J , et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. J Clin Oncol 1996;14:35-45
Web of Science | Medline27
Crump M ,Tu DS ,Shepherd L ,Levine M ,Bramwell V ,Pritchard K . Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003;21:3066-3071
CrossRef | Web of Science | Medline28
Praga C ,Bergh J ,Bliss J , et al. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol 2005;23:4179-4191
CrossRef | Web of Science | Medline29
Pulsoni A ,Pagano L ,Lo Coco F , et al. Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience. Blood 2002;100:1972-1976
CrossRef | Web of Science | Medline30
Detourmignies L ,Castaigne S ,Stoppa AM , et al. Therapy-related acute promyelocytic leukemia: a report on 16 cases. J Clin Oncol 1992;10:1430-1435
Web of Science | Medline31
Leonard RC ,Lind M ,Twelves C , et al. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. J Natl Cancer Inst 2004;96:1076-1083
CrossRef | Web of Science | Medline32
Gianni L ,Baselga J ,Eiermann W , et al. European Cooperative Trial in Operable Breast Cancer (ECTO): improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrexate and fluorouracil (CMF). J Clin Oncol 2005;23:Suppl:7S-7S
CrossRef | Web of Science33
Hopwood P ,Ellis P ,Barrett-Lee P , et al. Impact on quality of life (QL) during chemotherapy (CT) of FEC-T compared to FEC or E-CMF: results from the UKNCRI Taxotere as Adjuvant Chemotherapy Trial (TACT). J Clin Oncol 2005;23:Suppl:43S-43S
Web of Science34
Piccart-Gebhart MJ ,Proctor M ,Leyland-Jones B , et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672
Full Text | Web of Science | Medline35
Buzdar AU ,Ibrahim NK ,Francis D , et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23:3676-3685
CrossRef | Web of Science | Medline
- Citing Articles (54)
Citing Articles
1
Mustafa Khasraw, Richard Bell, Chau Dang. (2012) Epirubicin: Is it like doxorubicin in breast cancer? A clinical review. The Breast
CrossRef2
Markus Joerger, Beat Thürlimann, Anita Savidan, Harald Frick, Christine Bouchardy, Isabelle Konzelmann, Nicole Probst-Hensch, Silvia Ess. (2011) A Population-Based Study on the Implementation of Treatment Recommendations for Chemotherapy in Early Breast Cancer. Clinical Breast Cancer
CrossRef3
Ian H. Kunkler, Gillian R. Kerr, Jeremy S. Thomas, Wilma J.L. Jack, John M.S. Bartlett, Hans C. Pedersen, David A. Cameron, J. Michael Dixon, Udi Chetty. (2011) Impact of Screening and Risk Factors for Local Recurrence and Survival After Conservative Surgery and Radiotherapy for Early Breast Cancer: Results from a Large Series with Long-Term Follow-Up. International Journal of Radiation Oncology*Biology*Physics
CrossRef4
William E. Pierceall, Kam M. Sprott, Tuomas Heikkinen, Paivi Heikkila, Lakshmi Alaparthi, Kristiina Aittomaki, Mohammed El-Adhami, Vivian Villegas-Bergazzi, Jane L. Meyer, Jeffery L. Kutok, Jirina Bartkova, Jiri Bartek, Heli Nevanlinna, David T. Weaver, Carl Blomqvist. (2011) Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer. Human Pathology
CrossRef5
Elisabeth Luporsi, Fabrice André, Frédérique Spyratos, Pierre-Marie Martin, Jocelyne Jacquemier, Frédérique Penault-Llorca, Nicole Tubiana-Mathieu, Brigitte Sigal-Zafrani, Laurent Arnould, Anne Gompel, Caroline Egele, Bruno Poulet, Krishna B. Clough, Hubert Crouet, Alain Fourquet, Jean-Pierre Lefranc, Carole Mathelin, Nicolas Rouyer, Daniel Serin, Marc Spielmann, Margaret Haugh, Marie-Pierre Chenard, Etienne Brain, Patricia de Cremoux, Jean-Pierre Bellocq. (2011) Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Research and Treatment
CrossRef6
H.E. Campbell, D. Epstein, D. Bloomfield, S. Griffin, A. Manca, J. Yarnold, J. Bliss, L. Johnson, H. Earl, C. Poole, L. Hiller, J. Dunn, P. Hopwood, P. Barrett-Lee, P. Ellis, D. Cameron, A.L. Harris, A.M. Gray, M.J. Sculpher. (2011) The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses. European Journal of Cancer 47:17, 2517-2530
CrossRef7
Angelo Di Leo, Christine Desmedt, John M S Bartlett, Fanny Piette, Bent Ejlertsen, Kathleen I Pritchard, Denis Larsimont, Christopher Poole, Jorma Isola, Helena Earl, Henning Mouridsen, Frances P O'Malley, Fatima Cardoso, Minna Tanner, Alison Munro, Chris J Twelves, Christos Sotiriou, Lois Shepherd, David Cameron, Martine J Piccart, Marc Buyse. (2011) HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. The Lancet Oncology 12:12, 1134-1142
CrossRef8
S. Aebi, T. Davidson, G. Gruber, F. Cardoso, . (2011) Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 22:Supplement 6, vi12-vi24
CrossRef9
Jordi Ginés, Eliazar Sabater, Clara Martorell, María Grau, Marta Monroy, Miguel A. Casado. (2011) Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta-analysis of randomised clinical trials. Clinical and Translational Oncology 13:7, 485-498
CrossRef10
F. P. O’Malley, S. Chia, D. Tu, L. E. Shepherd, M. N. Levine, D. Huntsman, V. H. Bramwell, I. L. Andrulis, K. I. Pritchard. (2011) Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial. Breast Cancer Research and Treatment 128:2, 401-409
CrossRef11
E. Munzone, G. Curigliano, H. J. Burstein, E. P. Winer, A. Goldhirsch. (2011) CMF revisited in the 21st century. Annals of Oncology
CrossRef12
Melanie Spears, Karen J. Taylor, Alison F. Munro, Carrie A. Cunningham, Elizabeth A. Mallon, Chris J. Twelves, David A. Cameron, Jeremy Thomas, John M. S. Bartlett. (2011) In situ detection of HER2:HER2 and HER2:HER3 protein–protein interactions demonstrates prognostic significance in early breast cancer. Breast Cancer Research and Treatment
CrossRef13
Luke Nolan, Angela Darby, Katia Boleti, Peter Simmonds. (2011) The incidence of symptomatic thromboembolism in patients receiving adjuvant anthracycline-based chemotherapy for early stage breast cancer. The Breast 20:2, 151-154
CrossRef14
Orit Freedman, Eitan Amir, Camilla Zimmermann, Mark Clemons. (2011) Filling in the gaps: reporting of concurrent supportive care therapies in breast cancer chemotherapy trials. Supportive Care in Cancer 19:3, 315-322
CrossRef15
Hans Wildiers, Marcel Reiser. (2011) Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma. Critical Reviews in Oncology/Hematology 77:3, 221-240
CrossRef16
J. Lemieux, P. J. Goodwin, L. J. Bordeleau, S. Lauzier, V. Theberge. (2011) Quality-of-Life Measurement in Randomized Clinical Trials in Breast Cancer: An Updated Systematic Review (2001-2009). JNCI Journal of the National Cancer Institute 103:3, 178-231
CrossRef17
Sandra A OʼToole, Christina I Selinger, Ewan K A Millar, Trina Lum, Jane M Beith. (2011) Molecular assays in breast cancer pathology. Pathology 43:2, 116-127
CrossRef18
Ashley Davidson, Karen Gelmon. (2011) Do anthracyclines still have a role in adjuvant chemotherapy of breast cancer?. Future Oncology 7:1, 37-55
CrossRef19
A F Munro, D A Cameron, J M S Bartlett. (2010) Targeting anthracyclines in early breast cancer: new candidate predictive biomarkers emerge. Oncogene 29:38, 5231-5240
CrossRef20
Katrín Á. Gunnarsdóttir, Maj-Britt Jensen, David Zahrieh, Richard D. Gelber, Ann Knoop, Marco Bonetti, Henning Mouridsen, Bent Ejlertsen. (2010) CEF is superior to CMF for tumours with TOP2A aberrations: a Subpopulation Treatment Effect Pattern Plot (STEPP) analysis on Danish Breast Cancer Cooperative Group Study 89D. Breast Cancer Research and Treatment 123:1, 163-169
CrossRef21
Emad A. Rakha, Jorge S. Reis-Filho, Ian O. Ellis. (2010) Combinatorial biomarker expression in breast cancer. Breast Cancer Research and Treatment 120:2, 293-308
CrossRef22
John MS Bartlett, Alison F Munro, Janet A Dunn, Christopher McConkey, Sarah Jordan, Chris J Twelves, David A Cameron, Jeremy Thomas, Fiona M Campbell, Daniel W Rea, Elena Provenzano, Carlos Caldas, Paul Pharoah, Louise Hiller, Helena Earl, Christopher J Poole. (2010) Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). The Lancet Oncology 11:3, 266-274
CrossRef23
Q. Ghafoor, P. Sanghera, R.J. Grieve. (2010) A Study of Medical Intervention in Routine Breast Cancer Follow-up. Clinical Oncology 22:2, 91-96
CrossRef24
, Paula Manchon, Josep M. Borràs, Tàrsila Ferro, Josep Alfons Espinàs. (2010) Breast cancer OncoGuia. Clinical and Translational Oncology 12:2, 113-137
CrossRef25
Philippe L. Bedard, Angelo Di Leo, Martine J. Piccart-Gebhart. (2010) Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. Nature Reviews Clinical Oncology 7:1, 22-36
CrossRef26
Ian H. Kunkler. (2009) Radiotherapy of the regional lymph nodes: shooting at the sheriff?. The Breast 18, S112-S120
CrossRef27
Peng Huang, Christopher G. Goetz, Robert F. Woolson, Barbara Tilley, Douglas Kerr, Yuko Palesch, Jordan Elm, Bernard Ravina, Kenneth J. Bergmann, Karl Kieburtz. (2009) Using global statistical tests in long-term Parkinson's disease clinical trials. Movement Disorders 24:12, 1732-1739
CrossRef28
D Krell, A L Jones. (2009) Impact of effective prevention and management of febrile neutropenia. British Journal of Cancer 101, S23-S26
CrossRef29
Manfred Schmitt, Fred C.G.J. Sweep. (2009) Tissue inhibitor metalloproteinase type-1 (TIMP-1), a novel cancer biomarker predicting response of adjuvant anthracycline-based chemotherapy in patients afflicted with primary breast cancer. European Journal of Cancer 45:14, 2444-2446
CrossRef30
M Verrill. (2009) Chemotherapy for early-stage breast cancer: a brief history. British Journal of Cancer 101, S2-S5
CrossRef31
Feng Bai, Charles H. Fraga, Michael Tagen, Paula Schaiquevich, Nikolaus Hagedorn, Clinton F. Stewart. (2009) Simultaneous determination of cyclophosphamide and carboxyethylphosphoramide mustard in human plasma using online extraction and electrospray tandem mass spectrometry (HTLC–ESI-MS/MS). Journal of Chromatography B 877:18-19, 1709-1715
CrossRef32
Tsz-Kok YAU, Ting-Ying NG, Inda Sung SOONG, Chi-Wai CHOI, ka-On LAM, Alice Wan-Ying NG, Anne Wing-Mui LEE, Yuk TUNG. (2009) Toxicity of docetaxel plus cyclophosphamide as adjuvant therapy for breast cancer in Chinese patients - the Hong Kong experience. Asia-Pacific Journal of Clinical Oncology 5:2, 123-128
CrossRef33
Paul Ellis, Peter Barrett-Lee, Lindsay Johnson, David Cameron, Andrew Wardley, Susan O'Reilly, Mark Verrill, Ian Smith, John Yarnold, Robert Coleman, Helena Earl, Peter Canney, Chris Twelves, Christopher Poole, David Bloomfield, Penelope Hopwood, Stephen Johnston, Mitchell Dowsett, John MS Bartlett, Ian Ellis, Clare Peckitt, Emma Hall, Judith M Bliss. (2009) Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. The Lancet 373:9676, 1681-1692
CrossRef34
Angelo Di Leo, Laura Biganzoli, Wederson Claudino, Sara Licitra, Marta Pestrin, Denis Larsimont. (2008) Topoisomerase II alpha as a marker predicting anthracyclines’ activity in early breast cancer patients: Ready for the primetime?. European Journal of Cancer 44:18, 2791-2798
CrossRef35
H M Earl, L Hiller, J A Dunn, S Bathers, P Harvey, A Stanley, R J Grieve, R K Agrawal, I N Fernando, A M Brunt, K McAdam, S O'Reilly, D W Rea, D Spooner, C J Poole. (2008) NEAT: National Epirubicin Adjuvant Trial – toxicity, delivered dose intensity and quality of life. British Journal of Cancer 99:8, 1226-1231
CrossRef36
A M Wardley, L Hiller, H C Howard, J A Dunn, A Bowman, R E Coleman, I N Fernando, D M Ritchie, H M Earl, C J Poole. (2008) tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation. British Journal of Cancer 99:4, 597-603
CrossRef37
V Gouyer, D Fontaine, P Dumont, O de Wever, H Fontayne-Devaud, E Leteurtre, S Truant, D Delacour, H Drobecq, J-P Kerckaert, Y de Launoit, M Bracke, C Gespach, J-L Desseyn, G Huet. (2008) Autocrine induction of invasion and metastasis by tumor-associated trypsin inhibitor in human colon cancer cells. Oncogene 27:29, 4024-4033
CrossRef38
L. Raffaghello, C. Lee, F. M. Safdie, M. Wei, F. Madia, G. Bianchi, V. D. Longo. (2008) From the Cover: Reactive Oxygen Species Special Feature: Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proceedings of the National Academy of Sciences 105:24, 8215-8220
CrossRef39
C. Thomssen, J. Huober. (2008) Primäre und adjuvante Systemtherapie des operablen Mammakarzinoms. Der Onkologe 14:5, 504-513
CrossRef40
Amy Trentham-Dietz, Brian L. Sprague, Ronald Klein, Barbara E. K. Klein, Karen J. Cruickshanks, Dennis G. Fryback, John M. Hampton. (2008) Health-related quality of life before and after a breast cancer diagnosis. Breast Cancer Research and Treatment 109:2, 379-387
CrossRef41
Lionel Apetoh, Grégoire Mignot, Theocharis Panaretakis, Guido Kroemer, Laurence Zitvogel. (2008) Immunogenicity of anthracyclines: moving towards more personalized medicine. Trends in Molecular Medicine 14:4, 141-151
CrossRef42
I.H. Kunkler, P. Canney, G. van Tienhoven, N.S. Russell. (2008) Elucidating the Role of Chest Wall Irradiation in ‘Intermediate-risk’ Breast Cancer: the MRC/EORTC SUPREMO Trial. Clinical Oncology 20:1, 31-34
CrossRef43
P. Francis, J. Crown, A. Di Leo, M. Buyse, A. Balil, M. Andersson, B. Nordenskjold, I. Lang, R. Jakesz, D. Vorobiof, J. Gutierrez, G. van Hazel, S. Dolci, S. Jamin, B. Bendahmane, R. D. Gelber, A. Goldhirsch, M. Castiglione-Gertsch, M. Piccart-Gebhart, . (2008) Adjuvant Chemotherapy With Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02 98 Randomized Trial. JNCI Journal of the National Cancer Institute 100:2, 121-133
CrossRef44
D Faratian, J Bartlett. (2008) Predictive markers in breast cancer - the future. Histopathology 52:1, 91-98
CrossRef45
Luca Santucci, Andrea Mencarelli, Barbara Renga, Daniela Ceccobelli, Gianfranco Pasut, Francesco M. Veronese, Eleonora Distrutti, Stefano Fiorucci. (2007) Cardiac safety and antitumoral activity of a new nitric oxide derivative of pegylated epirubicin in mice. Anti-Cancer Drugs 18:9, 1081-1091
CrossRef46
Peter S Grimison, Martin R Stockler. (2007) Quality of life and adjuvant systemic therapy for early-stage breast cancer. Expert Review of Anticancer Therapy 7:8, 1123-1134
CrossRef47
Ian Kunkler, Geertjan van Tienhoven, Michael Dixon, Robin Prescott, Nicola Russell, Peter Canney, Joanna Dunlop. (2007) Postmastectomy radiotherapy should not be standard of care for women with 1–3 involved nodes. Radiotherapy and Oncology 84:1, 103-104
CrossRef48
Heather L. McArthur, Clifford A. Hudis. (2007) Breast Cancer Chemotherapy. The Cancer Journal 13:3, 141-147
CrossRef49
Costa, Serban-Dan, Bischoff, Joachim, . (2007) Adjuvant Therapy for Early Breast Cancer. New England Journal of Medicine 356:12, 1268-1269
Full Text50
Bent Ejlertsen, Henning T. Mouridsen, Maj-Britt Jensen, Jørn Andersen, Søren Cold, Per Edlund, Marianne Ewertz, Brita B. Jensen, Claus Kamby, Bo Nordenskjold, Jonas Bergh. (2007) Improved outcome from substituting methotrexate with epirubicin: Results from a randomised comparison of CMF versus CEF in patients with primary breast cancer. European Journal of Cancer 43:5, 877-884
CrossRef51
T. Gelder. (2007) Adjuvante chemotherapie bij mammacarcinoom. Medisch-Farmaceutische Mededelingen 45:3, 76-76
CrossRef52
T.J. Eberlein. (2007) Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast Cancer. Yearbook of Surgery 2007, 299-301
CrossRef53
L.P. Shulman. (2007) Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast Cancer. Yearbook of Obstetrics, Gynecology and Women's Health 2007, 245-247
CrossRef54
Levine, Mark N., Whelan, Timothy, . (2006) Adjuvant Chemotherapy for Breast Cancer — 30 Years Later. New England Journal of Medicine 355:18, 1920-1922
Full Text
- Glossary
Glossary of Chemotherapy Schedules
-
Classic CMF:
Six cycles of cyclophosphamide (100 mg per square meter of body-surface area given orally every day for 14 days or, at the clinician's preference, 600 mg per square meter given intravenously on days 1 and 8) with methotrexate (40 mg per square meter) and fluorouracil (600 mg per square meter) given intravenously on days 1 and 8 of the cycle.
-
Modified CMF in the BR9601 trial:
Eight cycles of cyclophosphamide (750 mg per square meter), methotrexate (50 mg per square meter), and fluorouracil (600 mg per square meter), all given intravenously on day 1 every 3 weeks.
-
Epirubicin plus CMF in NEAT:
Four cycles of epirubicin (100 mg per square meter) every 3 weeks, followed by four cycles of classic CMF.
-
Epirubicin plus CMF in the BR9601 trial:
Four cycles of epirubicin (100 mg per square meter) every 3 weeks, followed by four cycles of the modified CMF schedule.
-
FEC100:
Fluorouracil (500 mg per square meter), epirubicin (100 mg per square meter), and cyclophosphamide (500 mg per square meter), all given intravenously every 3 weeks.
-
FEC50:
Fluorouracil (500 mg per square meter), epirubicin (50 mg per square meter), and cyclophosphamide (500 mg per square meter), all given intravenously every 3 weeks.
-
CEF:
Cyclophosphamide (75 mg per square meter), given orally every day for 14 days; epirubicin (60 mg per square meter) and fluorouracil (500 mg per square meter), both given intravenously on days 1 and 8 every 4 weeks for six cycles (with routine antibiotic prophylaxis).
-
Doxorubicin plus CMF:
Doxorubicin (75 mg per square meter) given every 3 weeks for four cycles, followed by four cycles of classic CMF.
-
Doxorubicin and paclitaxel plus CMF:
Doxorubicin (60 mg per square meter) and paclitaxel (200 mg per square meter), both given intravenously every 3 weeks for four cycles, followed by intravenous cyclophosphamide (600 mg per square meter), methotrexate (40 mg per square meter), and fluorouracil (600 mg per square meter) on days 1 and 8 every 4 weeks for four cycles.
-
FEC plus docetaxel:
Fluorouracil (600 mg per square meter), epirubicin (60 mg per square meter), and cyclophosphamide (600 mg per square meter), all given intravenously every 3 weeks for four cycles, followed by docetaxel (100 mg per square meter) given intravenously every 3 weeks for four cycles (with routine antibiotic prophylaxis).
-
- Letters
